Human Molecular Genetics Advance Access originally published online on March 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, 2004, Vol. 13, No. 9 893-903
DOI: 10.1093/hmg/ddh105
Human Molecular Genetics, Vol. 13, No. 9 © Oxford University Press 2004; all rights reserved
Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo
1Institute of Biochemistry, Department of Molecular Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany, 2Institute of Pharmacology, Medical Faculty, Free University Berlin, Berlin, Germany and 3Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
Received November 11, 2003; Accepted February 2, 2004
Many human diseases are caused by inactivating mutations in specific G-protein-coupled receptors (GPCRs). In about 10% of these cases, a premature stop codon leads to the generation of a truncated, functionally inactive receptor protein. In this study, we tested the hypothesis that such GPCR mutations can be functionally rescued in vitro and in vivo by treatment with aminoglycoside antibiotics, which are known for their ability to suppress premature termination codons. As a model system, we studied a mutant V2 vasopressin receptor (AVPR2) containing the inactivating E242X nonsense mutation which mimics human X-linked nephrogenic diabetes insipidus (XNDI) when introduced into mice via gene targeting techniques. Studies with cultured mammalian cells expressing the E242X mutant receptor showed that G418 (geneticin) was by far the most potent aminoglycoside antibiotic capable of suppressing the E242X nonsense codon. Strikingly, G418 treatment increased AVP-mediated cAMP responses in cultured kidney collecting duct cells prepared from E242X mutant mice in vitro, and significantly improved the urine-concentrating ability of E242X mutant mice in vivo. This is the first study demonstrating that G418 (aminoglycosides) can ameliorate the clinical symptoms of a disease-causing premature stop codon in a member of the GPCR superfamily.
* To whom correspondence should be addressed at: Institute of Biochemistry, Department of Molecular Biochemistry (Max–Planck Institute Interim), Medical Faculty, University of Leipzig, Deutscher Platz 6, 04103 Leipzig, Germany. Tel.: +49 3413550850; Fax: +49 3413550855; Email: schoberg{at}medizin.uni-leipzig.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Yang, J. Feng, W. Song, J. Wang, B. Tsai, Y. Zhang, W. A. Scaringe, K. A. Hill, P. Margaritis, K. A. High, et al. A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin PNAS, September 25, 2007; 104(39): 15394 - 15399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Robben, N. V. A. M. Knoers, and P. M. T. Deen Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol, August 1, 2006; 291(2): F257 - F270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Fujiwara and D. G. Bichet Molecular Biology of Hereditary Diabetes Insipidus J. Am. Soc. Nephrol., October 1, 2005; 16(10): 2836 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Lai, H. H. Chun, S. A. Nahas, M. Mitui, K. M. Gamo, L. Du, and R. A. Gatti Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons PNAS, November 2, 2004; 101(44): 15676 - 15681. [Abstract] [Full Text] [PDF]
|
|